SMTI, US79957L1008

Sanara MedTech stock: Q3 revenue grows as 2026 outlook is cut

Published on 11/20/2026 at 00:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanara MedTech stock posted stronger quarterly revenue and Adjusted EBITDA. Merger-related costs and a lower 2026 outlook weigh on the earnings picture.

Key quarterly developments

  • Third-quarter revenue increased 8 percent year over year, while Adjusted EBITDA rose to 5.6 million US dollars.
  • Sanara lowered its 2026 revenue outlook as merger-related costs pushed continuing operations into a net loss.
SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech reported third-quarter results on November 12, 2026, with revenue growth offset by higher expenses and a lower full-year outlook. The company said net revenue rose 8 percent year over year to 28.4 million US dollars for the quarter ended September 30.

Revenue growth meets higher costs

Gross profit reached 26.3 million US dollars, equal to a 93 percent margin, compared with 24.5 million US dollars a year earlier. Operating income fell to 0.7 million US dollars from 2.9 million US dollars, while operating expenses increased 19 percent to 25.6 million US dollars.

Sanara recorded a 1.3 million US dollar loss from continuing operations, compared with income of 0.8 million US dollars in the prior-year quarter. The company attributed the pressure in part to approximately 3.0 million US dollars in legal and advisory services linked to corporate initiatives and its pending merger with MiMedx Group.

Adjusted EBITDA increased to 5.6 million US dollars from 4.9 million US dollars. Management identified CellerateRX Surgical and BIASURGE as important revenue drivers, while bone fusion product sales declined slightly during the quarter.

Lower outlook keeps merger in focus

Sanara lowered its 2026 net revenue guidance to 110 million to 115 million US dollars from 116 million to 121 million US dollars. The revised range implies growth of 7 percent to 12 percent over 2025 revenue of 103.1 million US dollars.

Shareholders approved the proposed combination with MiMedx in September, but the transaction remained subject to regulatory review in the company's November 12 release. The merger therefore remains an important next step for investors assessing Sanara's operating costs, strategic direction and prospective ownership change.

Sanara MedTech stock was last quoted at 32.67 US dollars on Nasdaq at 4:00 p.m. ET on Thursday, November 19, 2026.

Surgical technology specialist

Sanara MedTech develops, markets and distributes surgical products for physicians and hospitals, with its portfolio focused on tissue repair, wound care and bone fusion. Its products include CellerateRX Surgical, BIASURGE, FORTIFY tissue-repair products and other biologic solutions. The Fort Worth, Texas-based company primarily serves the North American surgical tissue-repair market and operates as a smaller specialist within medical instruments and supplies.

Sanara MedTech at a glance

  • Company: Sanara MedTech Inc.
  • ISIN: US79957L1008
  • Ticker: SMTI
  • Exchange: Nasdaq
  • Last quoted price: 32.67 US dollars at 4:00 p.m. ET on November 19, 2026
  • Market capitalization: 300,002,860 US dollars
  • 52-week range: 16.05 to 35.52 US dollars

Investors can follow the S&P 500 market environment alongside company-specific developments.

More news and analyses on Sanara MedTech stock are available on the company topic page.

Source: Sanara MedTech third-quarter release.

Disclaimer...
en | US79957L1008 | SMTI | boerse | 70538153 | bgmi